천식 : 시장 인사이트, 역학 및 예측(2024-2032년)

The asthma market refers to the market for products that are used to address this condition through the creation, manufacturing, and sale of drugs, devices, and therapies that help control and treat asthma, a long-term illness that results in inflammation of airways and constriction of the bronchi. There is a growing focus on respiratory diseases and the development of new treatments wherein the growth of the market is attributed to the increasing incidences of asthma, the growing awareness among people about respiratory wellness, and the emerging options in the form of new inhalers and biologics. Also, there are more favorable governmental policies and higher consumer demand for individualized treatment, which complements conceptions of therapy adherence and results in better asthma management market trends.

The asthma market is expected to grow around ~5% during the forecast period (2024-2032). The Increasing incidence of asthma globally is due to environmental factors, allergens, and lifestyle changes that drive the growth of the asthma market. Also, ongoing research and development of new drugs and biologics targeting asthma control. For instance, in February 2023, Pulmatrix initiated a Phase 2b trial, dosing the first patient with PUR1900 for Allergic Bronchopulmonary Aspergillosis (ABPA) and asthma. The global study will assess safety, tolerability, and efficacy over 16 weeks, supporting Pulmatrix's collaboration with Cipla to bring therapy to patients with asthma, with proof-of-concept data expected by mid-2024.

Based on the marketed therapies, the market has been divided into TEZSPIRE, TRELEGY ELLIPTA, ARNUITY ELLIPTA, CINQAIR (reslizumab), FASENRA, (benralizumab), DUPIXENT (dupilumab), NUCALA (mepolizumab), AIRSUPRA (albuterol and budesonide), and XOLAIR (omalizumab). Among them, the TEZSPIRE held a significant market share in 2023. TEZSPIRE, a marketed therapy for severe asthma, is significantly driving the asthma market by offering a novel and effective treatment option for patients with uncontrolled asthma despite standard therapies. Its unique mechanism of action targets and inhibits thymic stromal lymphopoietin (TSLP), a key driver of asthma inflammation, providing broader efficacy across various types of severe asthma. The development of TEZSPIRE responds to a therapeutic need and contributes to the enhancement of the patient's status and the decrease in the number of exacerbations. Besides broadening the therapeutic approach, this therapy contributes to market development by increasing the use of new medical products by physicians and increasing investment in the development of innovative biologicals for respiratory diseases.

For a better understanding of the market adoption of asthma disease, the market is analyzed based on its 7MM presence in countries such as The U.S., Germany, the UK, France, Italy, Spain, and Japan. The U.S. held a dominant share of the market in 2023. The U.S. market for asthma diseases is substantial, driven by the high prevalence and significant healthcare burden of the disease. For instance, the current asthma prevalence among adults in the U.S. increased from 6.9% in 2001 to 8.0% in 2021. Larger populations aware and diagnosed, coupled with improved treatment choices, are the factors that help in the expansion of the market. The presence of novel treatment, including biologics, in combination with the common inhalers and tablets improves the control of both intermittent and severe asthma. The demand for healthcare facilities and innovations to decrease air pollution and enhance existing structures along with strong investment in pharmaceutical production by governments and companies also stimulate the market.

Some of the major players operating in the market include AstraZeneca, GSK plc, Cipla, Teva Pharmaceutical Industries Ltd., Sanofi, Avillion LLP, Novartis AG, CHIESI Farmaceutici S.p.A., Boehringer Ingelheim International GmbH, and AB Science.

TABLE OF CONTENTS

1.MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2.RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Asthma Market
• 2.2. Research Methodology of the Asthma Market
• 2.3. Respondent Profile

3.EXECUTIVE SUMMARY

• 3.1. Industry Synopsis
• 3.2. Segmental Outlook
  • 3.2.1. Market Growth Intensity
• 3.3. Regional Outlook

4.MARKET DYNAMICS

• 4.1. Drivers
• 4.2. Opportunity
• 4.3. Restraints
• 4.4. Trends

5.DISEASE BACKGROUND AND OVERVIEW

• 5.1. Introduction
• 5.2. Classification
• 5.3. Causes
• 5.4. Risk Factors
• 5.5. Signs and Symptoms
  • 5.5.1. Early Signs and Symptoms
  • 5.5.2. Progressed Symptoms
• 5.6. Diagnosis
  • 5.6.1. Physical exam
  • 5.6.2. Lung Function Tests

6.TREATMENT

• 6.1. First Line Treatment - Inhaled corticosteroids (ICS)
• 6.2. Bronchial Thermoplasty
• 6.3. Anti-inflammatory
• 6.4. Combination Medicines
• 6.5. Anticholinergics
• 6.6. Biologics
• 6.7. Antibiotics
• 6.8. Others
• 6.9. Emerging Therapies
  • 6.9.1. Immunotherapy
  • 6.9.2. Others

7.PATIENT JOURNEY

8.GUIDELINES ON ASTHMA

• 8.1. NICE Recommendations for Asthma Management
• 8.2. British Guidelines on the Management of Asthma
• 8.3. International ERS/ATS Guidelines on the Definition, Evaluation, and Treatment of Severe Asthma
• 8.4. Other Guidelines for Asthma

9.EPIDEMIOLOGY & PATIENT POPULATION, 2022-2032F

• 9.1. Assumptions and Rationale
• 9.2. Epidemiology of Asthma in 7MM
  • 9.2.1. Total Prevalent Population of Asthma in the 7MM
  • 9.2.2. Severity-specific cases of Asthma
  • 9.2.3. Type-specific cases of Severe Asthma
  • 9.2.4. Age-specific Prevalent Population of Asthma in the 7MM

10.EPIDEMIOLOGY OF ASTHMA BY COUNTRY

• 10.1. The United States
  • 10.1.1. Total Prevalent Population of Asthma in the 7MM
  • 10.1.2. Severity-specific cases of Asthma
  • 10.1.3. Type-specific cases of Severe Asthma
  • 10.1.4. Age-specific Prevalent Population of Asthma in the 7MM
• 10.2. Germany
• 10.3. UK
• 10.4. France
• 10.5. Italy
• 10.6. Spain
• 10.7. Japan

11.ASTHMA MARKET INSIGHTS, MARKETED THERAPIES

• 11.1. TEZSPIRE (tezepelumab-ekko): Amgen/AstraZeneca
  • 11.1.1. Drug Profile
  • 11.1.2. Regulatory Achievements
  • 11.1.3. Other Development Activities
  • 11.1.4. Clinical Development
  • 11.1.5. Safety and Efficacy
• 11.2. TRELEGY ELLIPTA (fluticasone furoate/umeclidinium/vilanterol): GlaxoSmithKline
• 11.3. ARNUITY ELLIPTA (fluticasone furoate inhalation powder): GlaxoSmithKline
• 11.4. CINQAIR (reslizumab): Teva Pharmaceutical
• 11.5. FASENRA (benralizumab): AstraZeneca
• 11.6. DUPIXENT (dupilumab): Sanofi and Regeneron Pharmaceutical
• 11.7. NUCALA (mepolizumab): GlaxoSmithKline (GSK)
• 11.8. AIRSUPRA (albuterol and budesonide): AstraZeneca/Avillion
• 11.9. XOLAIR (omalizumab): Novartis

Complete List in the report

12.ASTHMA MARKET INSIGHTS, EMERGING THERAPIES

• 12.1. GSK3511294 (Depemokimab): GlaxoSmithKline
  • 12.1.1. Drug Profile
  • 12.1.2. Clinical Development
  • 12.1.3. Safety and Efficacy
• 12.2. Givinostat: Italfarmaco
• 12.3. Masitinib (AB07105): AB Science
• 12.4. PT010: AstraZeneca
• 12.5. Dexpramipexole Dihydrochloride: Areteia Therapeutics
• 12.6. PBF-680: Palobiofarma SL/Pivotal S.L.
• 12.7. ARS 1: ARS Pharmaceuticals, Inc.
• 12.8. MEDI3506 (tozorakimab): AstraZeneca
• 12.9. AZD1402 (PRS-060): Pieris Pharma/AstraZeneca
• 12.10. Atuliflapon (AZD5718): AstraZeneca
• 12.11. Amlitelimab: Sanofi

Complete List in the report

13.ASTHMA MARKET: 7MM ANALYSIS

• 13.1. Key Findings
• 13.2. Total Market Size of Asthma in the 7MM, 2022-2032F
• 13.3. Market Size of Asthma by Marketed Therapies in the 7MM
• 13.4. Market Size of Asthma by Emerging Therapies in the 7MM
• 13.5. United States Market Size, 2022-2032F
  • 13.5.1. Total Market Size of Asthma in the United States
  • 13.5.2. Market Size of Asthma by Marketed Therapies in the United States
  • 13.5.3. Market Size of Asthma by Emerging Therapies in the United States
• 13.6. Germany
• 13.7. UK
• 13.8. France
• 13.9. Italy
• 13.10. Spain
• 13.11. Japan

14.UNMET NEEDS

15.COMPETITIVE LANDSCAPE

• 15.1. Key Competitors - Marketed Therapies
• 15.2. Key Competitors - Phase III Drugs
• 15.3. Key Competitors - Phase II Drugs

16.COMPANY PROFILES

• 16.1. AstraZeneca
  • 16.1.1. Company Overview
  • 16.1.2. Key Financials
  • 16.1.3. SWOT Analysis
  • 16.1.4. Product Portfolio
  • 16.1.5. Recent Developments
• 16.2. GSK plc
• 16.3. Cipla
• 16.4. Teva Pharmaceutical Industries Ltd.
• 16.5. Sanofi
• 16.6. Avillion LLP
• 16.7. Novartis AG
• 16.8. CHIESI Farmaceutici S.p.A.
• 16.9. Boehringer Ingelheim International GmbH
• 16.10. AB Science

17.ACRONYMS & ASSUMPTION

18.ANNEXURE